# Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

> **NCT05170256** · PHASE2 · UNKNOWN · sponsor: **Morten Mau-Sørensen** · enrollment: 24 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma
- HER-2 Protein Overexpression
- HER-2 Gene Amplification

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT05170256
- **Lead sponsor:** Morten Mau-Sørensen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-04
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-08-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170256, "Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05170256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*